The outcome of cytoreductive radical prostatectomy for prostate cancer patients with bone metastasis

doi:10.3969/j.issn.1006-7795.2021.06.011

Abstract

Abstract: Objective To evaluate the clinical efficacy of cytoreductive radical prostatectomy in prostate cancer patients with bone metastasis. Methods A total of 34 prostate cancer patients with bone metastasis were included in this study,who underwent cytoreductive radical prostatectomy in the Department of Urology, Beijing Chaoyang Hospital, Capital Medical University from February 2012 to June 2021. Overall survival(OS) and biochemical progression-free survival (BPFS) were evaluated using descriptive statistical analyses, the Kaplan-Meier method, and univariate and multivariate analyses. Results The median follow-up time was 29.0 months, the 2-year OS was 85.9%, the median biochemical progression-free time was 75.0 months, and the 2-year BPFS was 63.9%.9 patients suffered Clavien-DindoⅠ-Ⅱ level complications within 1 month after surgery,and the patients’ urination function was basically recovered at 3 months after surgery. There were statistically significant differences in mean BPFS between the number of bone metastasis ≥5 and <5 group (28.1 months vs 63.2 months, P=0.012),and the positive and negative margins group(34.8 months vs 70.3 months, P=0.029). Multivariate analysis showed that positive/negative surgical margins was significantly associated with BPFS(P=0.026). Conclusion Prostate cancer with bone metastasis is not an absolute operational contraindication. The cytoreductive radical prostatectomy is safe and feasible for the patients after screening and preparation, with acceptable operation duration, bleeding volume and postoperative complications. The serum prostate specific antigen can be effectively controlled via combination treatment with endocrine therapy and other treatments after surgery, which is expected to improve disease progression and prolong the length of survival.

Key words: prostate cancer, bone metastasis, cytoreductive surgery, radical prostatectomy

CLC Number:

R737.25

Jiang Mingxin, Su Yao, Xiong Tianyu, Ye Xiaobo, Jin Song, Xing Nianzeng, Jin Mulan, Yang Mingfu, Niu Yinong. The outcome of cytoreductive radical prostatectomy for prostate cancer patients with bone metastasis[J]. Journal of Capital Medical University, 2021, 42(6): 967-972.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.06.011

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I6/967

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Mohler J L, Antonarakis E S, Armstrong A J, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2019, 17(5): 479-505.
[3] 中国抗癌协会泌尿男生殖系肿瘤专业委员会. 2018版转移性前列腺癌诊治中国专家共识[J]. 中华外科杂志, 2018, 56(9):646-652.
[4] Sooriakumaran P, Karnes J, Stief C, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation[J].Eur Urol, 2016, 69(5): 788-794.
[5] Steuber T, Berg K D, Røder M A, et al. Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? results from a prospective case-control study[J]. Eur Urol Focus, 2017, 3(6): 646-649.
[6] Culp S H, Schellhammer P F, Williams M B.Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study[J]. Eur Urol, 2014, 65(6): 1058-1066.
[7] Gratzke C, Engel J, Stief C G. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry[J]. Eur Urol, 2014, 66(3): 602-603.
[8] Fossati N, Trinh Q D, Sammon J, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study[J]. Eur Urol, 2015, 67(1): 3-6.
[9] Leyh-Bannurah S R, Gazdovich S, Budäus L, et al. Local therapy improves survival in metastatic prostate cancer[J]. Eur Urol, 2017, 72(1): 118-124.
[10] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019.[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[11] 马春光, 叶定伟, 李长岭, 等. 前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J]. 中华外科杂志,2008,46(12):921-925.
[12] Sweeney C J, Chen Y H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer[J]. N Engl J Med, 2015, 373(8): 737-746.
[13] Dubois N, Willems T, Myant N. Ovarian metastasis of breast cancer: a case report. Role of cytoreductive surgery[J].J Gynecol Obstet Biol Reprod, 2009, 38(3): 242-245.
[14] Frøysnes I S, Larsen S G, Spasojevic M, et al. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort[J]. J Surg Oncol, 2016, 114(2): 222-227.
[15] D'Hondt V, Goffin F, Roca L, et al. Interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in first-line treatment for advanced ovarian carcinoma: A feasibility study[J]. Int J Gynecol Cancer, 2016, 26(5): 912-917.
[16] Crispen P L, Blute M L. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma[J].Curr Urol Rep, 2012, 13(1): 38-46.
[17] Flanigan R C,Salmon S E, Blumenstein B A, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer[J]. N Engl J Med, 2001, 345(23): 1655-1659.
[18] Mathieu R, Korn S M, Bensalah K, et al. Cytoreductive radical prostatectomy in metastatic prostate cancer: does it really make sense?[J]. World J Urol, 2017, 35(4): 567-577.
[19] Kim D K, Parihar J S, Kwon Y S, et al. Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study[J]. Asian J Androl, 2018, 20(1): 9-14.
[20] 李高翔, 戴波, 叶定伟, 等. 寡转移性前列腺癌根治术的临床初步疗效观察及围手术期并发症分析[J]. 中国癌症杂志,2017,27(1):20-25.
[21] Silberstein J L, Poon S A, Sjoberg D D, et al. Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer[J]. BJU Int, 2015, 116(1): 50-56.
[22] Thalgott M, Horn T, Heck M M, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer[J]. J Hematol Oncol, 2014, 7: 20.
[23] 郑毅, 郑一春, 经霄, 等. 转移性前列腺癌手术治疗一例报告[J]. 中华泌尿外科杂志,2018,39(Z1):5-6.
[24] Löppenberg B, Dalela D, Karabon P, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis[J]. Eur Urol, 2017, 72(1): 14-19.